Adaptin Bio (APTN) Consolidated Net Income (2023 - 2026)

Adaptin Bio has disclosed Consolidated Net Income across 4 years of filings, most recently posting -$1.1 million for Q1 2026.

• Quarterly Consolidated Net Income fell 90.04% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.7 million (down 69.6% YoY) and the FY2025 annual result came in at -$5.2 million, down 66.53% from the prior year.
• Consolidated Net Income rose to -$1.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$34155.0 in Q4 2023 and bottomed at -$1.7 million in Q3 2025.
• The 4-year median for Consolidated Net Income is -$856836.0 (2024), against an average of -$867795.1.
• Year-over-year, Consolidated Net Income sank 2479.42% in 2024 and plunged 51.29% in 2025.
• Adaptin Bio's Consolidated Net Income stood at -$34155.0 in 2023, then sank by 2408.67% to -$856836.0 in 2024, then tumbled by 63.44% to -$1.4 million in 2025, then grew by 18.16% to -$1.1 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$1.1 million, -$1.4 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.